Clinical Trials Logo

Clinical Trial Summary

This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" [cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)] in the treatment of acute myeloid leukemia (AML) that has not responded well to standard therapy or has returned after an initial remission (relapsed). The trial will be conducted at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC). Potential participants will go through a screening period to see if they are eligible to join the study. If eligible, participants will be hospitalized for 4-5 weeks to receive study treatment with CLAG-GO, called induction chemotherapy. If tests show that the cancer is in remission after induction chemotherapy, participants may undergo further chemotherapy (known as consolidation) or may proceed with bone marrow/stem cell transplantation. Patients who receive consolidation chemotherapy and remain in remission may have up to 8 cycles of outpatient maintenance therapy. A cycle lasts about 28 days. All participants will be monitored carefully for both side effects and to see if the study treatment is working. Lab tests and exams will be conducted throughout the entire study. In addition, special studies will be done at various time points to try to understand better how the drugs work and which patients are likely to respond best.


Clinical Trial Description

This is a single-arm, two-stage phase II trial of cladribine, cytarabine, granulocyte colony stimulating factor and gemtuzumab ozogamicin (CLAG-GO) in adult patients with acute myeloid leukemia (AML) who are either have persistent disease after initial induction chemotherapy or are in first relapse, with early stopping for unacceptable toxicity. The trial will be conducted at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), with a target enrollment of 39 patients if the trial proceeds to the second stage. Eligible patients will receive induction chemotherapy with CLAG-GO at the doses detailed below. In the first stage of the trial, a sequential boundary is used to monitor induction mortality and halt accrual if this mortality is significantly above 10%. If more than 6 responses are seen in the initial 19 patients, 20 additional patients will be enrolled in the 2nd stage. Responders may proceed to allogeneic hematopoietic stem cell transplantation (alloHSCT) at any time after induction, and these patients will be monitored for at least 30 days post-transplantation for veno-occlusive disease. Responding patients will also have the option of having a single cycle of consolidation therapy using the same CLAG-GO regimen, followed by maintenance with GO monotherapy for up to 8 additional cycles. Responses will be categorized according to the European LeukemiaNet (ELN) response criteria for AML. Assessment of measureable residual disease (MRD) will be conducted with bone marrow aspirate samples and changes in immunophenotype will be evaluated. In addition, single nucleotide polymorphism (SNP) analysis and sialylation status of CD33, along with sialidase activity of myeloblasts will be evaluated and correlated with responses and survival times. Safety and toxicity will be evaluated continuously, and event-free survival, and overall survival as well as the proportion of patients proceeding to receive alloHSCT will be estimated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04050280
Study type Interventional
Source University of Maryland, Baltimore
Contact Larissa Sanglard
Phone 410-328-8370
Email Larissa.Sanglard@umm.edu
Status Recruiting
Phase Phase 2
Start date November 1, 2019
Completion date February 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05133882 - A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Phase 1/Phase 2
Active, not recruiting NCT05601726 - First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients Phase 1
Recruiting NCT06200441 - Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Recruiting NCT06449482 - Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy Phase 1/Phase 2
Not yet recruiting NCT06252584 - Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients Phase 1
Completed NCT05988047 - Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
Terminated NCT03951961 - Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Phase 2
Enrolling by invitation NCT03902665 - Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 Phase 2
Not yet recruiting NCT06285136 - Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult Phase 2/Phase 3
Recruiting NCT05127798 - RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
Recruiting NCT05906914 - Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06199557 - A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients Phase 1/Phase 2
Recruiting NCT04752527 - Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features Phase 2
Recruiting NCT03766126 - Lentivirally Redirected CD123 Autologous T Cells in AML Phase 1
Recruiting NCT05674539 - Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Phase 3
Enrolling by invitation NCT02985372 - Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia Phase 3
Recruiting NCT05703126 - Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML N/A
Recruiting NCT04240600 - Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay N/A
Terminated NCT04425655 - Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. Phase 2
Recruiting NCT04454580 - Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy